Combined therapies are also under investigation: the proteasome inhibitor Bortezomib combined with small molecules that inhibit IRE1α activity significantly decreased Multiple Myeloma growth in vivo53 as well as combining Bortezomib with the SERCA inhibitor Thapsigargin amplified ER stress and increased cancer cell death54. This evidence concerns the gene ERN1 and plasma cell myeloma.